Mechanism of Action for Leflunomide in Rheumatoid Arthritis

This publication has 56 references indexed in Scilit:

• Regulation of p53 stability by Mdm2
  Nature, 1997
• REGULATION OF B CELL FUNCTION BY THE IMMUNOSUPPRESSIVE AGENT LEFLUNOMIDE1
  Transplantation, 1996
• Dihydroorotate Dehydrogenase Is a High Affinity Binding Protein for A77 1726 and Mediator of a Range of Biological Effects of the Immunomodulatory Compound
  Journal of Biological Chemistry, 1995
• Leflunomide prevents the development of experimentally induced myasthenia gravis
  International Journal of Immunopharmacology, 1995
• The basis of autoimmunity: Part I mechanisms of aberrant self-recognition
  Immunology Today, 1995
• Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by the antibasement membrane antibody in rats
  Clinical Immunology and Immunopathology, 1991
• Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats
  International Journal of Immunopharmacology, 1989
• The use of the murine chronic graft Vs host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery
  Inflammation Research, 1987
• Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice
  Inflammation Research, 1986
• Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity — I. Disease modifying action on adjuvant arthritis of the rat
  International Journal of Immunopharmacology, 1985